Capillary electrophoresis for characterization of low molecular weight heparins

Laboratory Hematology

Volumn 9, Issue 2, 2003, Pages 64-66

  Ramasamy, Indra ^a,b   Kennedy, J ^a   Tan, K ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b Department of Health MDP14 ^*  (Australia)

Author keywords

Capillary eletrophoresis; Low molecular weight heparins

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BUFFER; COPPER SULFATE; DALTEPARIN; DISACCHARIDE; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OLIGOSACCHARIDE; PROTHROMBIN; SODIUM HYDROXIDE; SULFURIC ACID;

ACCURACY; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DERIVATIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HUMAN; MEDICAL INSTRUMENTATION; PH MEASUREMENT; REPRODUCIBILITY; SAMPLING; SEPARATION TECHNIQUE; STANDARDIZATION; TEMPERATURE MEASUREMENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

ELECTROPHORESIS, CAPILLARY; HEPARIN, LOW-MOLECULAR-WEIGHT; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 0345256504     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40:498-530.
2. ten Cate JW. Evolution of therapies in deep vein thrombosis management. Blood Coag Fibrin. 1999;10:S5-S10.
3. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med. 1995;155:601-607.
4. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Sem Thromb Haemost. 1999;25:5-16.
5. British Pharmacopoeia Organisation. Low molecular weight heparins. In: British Pharmacopoeia. London: British Pharmacopoeia Commission; 2002.
6. Desai UR, Wang H, Ampofo SA, Linhardt RJ. Oligosaccharide composition of heparin and low-molecular-weight heparins by capillary electrophoresis. Anal Biochem. 1993;213:120-127.
7. Pervin A, Al-Hakim A, Linhardt RJ. Separation of glycosaminoglycan-derived oligosaccharides by capillary electrophoresis using reverse polarity. Anal Biochem. 1994;221:182-188.
8. Toida T, Linhardt RJ. Detection of glycosaminoglycans as a copper (II) complex in capillary electrophoresis. Electrophoresis. 1996;17: 341-346.
9. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost. 1999;5(suppl 1):S63-S66.
10. Jeske W, Fareed J. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1999;25(suppl 3):27-33.
11. Samama MM, Bara L, Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. Drugs. 1996;52(suppl 7):8-14.
12. Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis. Thromb Res. 2000;100:V113-120.
13. Fareed J, Haas S, Sasahar A. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue. Semin Thromb Hemost. 1999;25(suppl 3):145-147.
14. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998;82:3L-10L.